Celltrion’s Remsima on track to become Korea’s 1st blockbuster drug

Quick Summary:

Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this year to become the first Korean drug to hit the milestone.

Remsima, the first biosimilar to Janssen’s Remicade, was approved by Europe as the world's first antibody biosimilar in 2013 and got the nod from the US Food and Drug Administration (FDA) in 2016.

Remsima has raked in 979.7 billion won in sales in the first three quarters ended in September, according to Celltrion on Monday.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: Economy

Markets: South Korea

Topics: First Europe Drug Sales Year Trillion Korean Remicade Celltrion Biosimilar Remsima

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-11-25 @ 17:15:47 (1 hours ago)

News Timezone: GMT +8:00

News Source URL: kedglobal.com

Language: English

Article Length: 320 words

Reading Time: 2 minutes read

Sentences: 21 lines

Sentence Length: 16 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Korea Economic Daily

News ID: 23818893

View Article Analysis

About Korea Economic Daily

Main Topics: Economy

Official Website: kedglobal.com

Update Frequency: 13 posts per day

Year Established: 1964

Headquarters: South Korea

News Last Updated: 39 minutes ago

Coverage Areas: South Korea

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #91

Publisher Details

Frequently Asked Questions